Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Follow-Up Questions
¿Quién es el CEO de Poxel SA?
Mr. Nicolas Trouche es el Chief Executive Officer de Poxel SA, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción PXXLF?
El precio actual de PXXLF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Poxel SA?
Poxel SA pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Poxel SA?
La capitalización bursátil actual de Poxel SA es $0
¿Es Poxel SA una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Poxel SA, incluyendo 3 fuerte compra, 5 compra, 1 mantener, 0 venta, y 3 fuerte venta
